Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen pharmacokinetics by CYP2D6*17 genotype in healthy Zimbabwean volunteers
PACTR202106791732070Phase 1Recruiting
- Sponsor
- AiBST
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tamoxifen in breast cancer (5 cohorts), sponsored by AiBST. Primary endpoints: Tamoxifen pharmacokinetics by CYP2D6 genotype and Formation of endoxifen by CYP2D6 genotype. Started Jan 2019; status: recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR202106791732070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202106791732070.